We are live on ! Find out more
RETA

Reata Pharmaceuticals, Inc. Class A Common Stock
RETA

Delisted

RETA was delisted on the 25th of September, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of RETA yet.

RETA Hedge Fund Activity: Q4 2023 in Review

0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2023, worth a combined $0 — down 100% from $2.98M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RETA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $2.93M sold.

  • 0 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2023, down from 2 in Q3 2023.
  • Funds reported $0 of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2023 was DekaBank Deutsche Girozentrale, an estimated $2.93M sold.

Based on aggregated 13F filings for Q4 2023.